Company Profile
Shenzhen Chipscreen Biosciences provides the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer.
Its portfolio also includes Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases, and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor.
Its portfolio also includes CS231295, a brain-penetrant Aurora B selective inhibitor, CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2, CS12088, a hepatitis B nucleocapsid assembly modulator, and CS12192 a highly selective JAK3 kinase inhibitor. Founded in 2001, the company is headquartered in Shenzhen, China.